{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:15:07Z","timestamp":1790252107592,"version":"4.1.0"},"reference-count":116,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Anemia is a common complication of chronic kidney disease; it is mainly treated with erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively investigated the mechanisms involved in the body\u2019s response to hypoxia and led to the discovery of the hypoxia-inducible factor (HIF) pathway and the enzymes regulating its function. HIF-prolyl-hydroxyl domain (PHD) inhibitors are a new class of oral drugs developed to treat anemia in chronic kidney disease. By inhibiting the function of PHD enzymes, they mimic the exposure to moderate hypoxia and stimulate the production of endogenous erythropoietin and very likely increase iron availability. Some data also suggest that their efficacy and, consequently, dose needs are less influenced by inflammation than ESAs. Overall, data from phases 2 and 3 clinical development showed efficacy in anemia correction and maintenance for all of the class molecules compared with placebo (superiority) or erythropoiesis-stimulating agents (noninferiority). Three molecules, roxadustat, vadadustat, and daprodustat, underwent extensive clinical investigation to assess their safety on hard cardiovascular end points, mortality, and special interest events (including cancer and thrombosis). Aside from vadadustat in the nondialysis population, at the prespecified primary analyses, all three molecules met the noninferiority margin for the risk of major cardiovascular events compared with erythropoiesis-stimulating agents or placebo. The reason for this discrepancy is difficult to explain. Other safety signals came from secondary analyses of some of the other randomized clinical trials, including a higher incidence of thrombosis. A more extensive clinical experience with post-marketing data on hard safety issues is needed to define better when and how to use HIF-PHD inhibitors compared with already available ESAs.<\/jats:p>","DOI":"10.1681\/asn.2022040413","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T15:30:13Z","timestamp":1661873413000},"page":"1966-1979","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Hypoxia-Inducible Factor\u2013Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?"],"prefix":"10.1681","volume":"33","author":[{"given":"Francesco","family":"Locatelli","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Alessandro Manzoni Hospital (past Director) ASST Lecco, Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant\u2019Anna Hospital, ASST Lariana, Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11]]},"reference":[{"key":"B1-20250823","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"B2-20250823","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2015.00167","article-title":"Renal erythropoietin-producing cells in health and disease","volume":"6","author":"Souma","year":"2015","journal-title":"Front Physiol"},{"key":"B3-20250823","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2007.06.008","article-title":"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target","volume":"50","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B4-20250823","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B5-20250823","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ki.2009.415","article-title":"A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment","volume":"77","author":"Szczech","year":"2010","journal-title":"Kidney Int"},{"key":"B6-20250823","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","article-title":"Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients","volume":"3","author":"Kilpatrick","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7-20250823","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"B8-20250823","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3\u2032 to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9-20250823","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B10-20250823","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00018-009-0147-7","article-title":"Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing","volume":"66","author":"Webb","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"B11-20250823","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Sch\u00f6del","year":"2011","journal-title":"Blood"},{"key":"B12-20250823","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"B13-20250823","doi-asserted-by":"crossref","first-page":"20551","DOI":"10.3390\/molecules201119717","article-title":"Recent advances in developing inhibitors for hypoxia-inducible factor prolyl hydroxylases and their therapeutic implications","volume":"20","author":"Kim","year":"2015","journal-title":"Molecules"},{"key":"B14-20250823","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"B15-20250823","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1242\/jcs.00318","article-title":"Intracellular localisation of human HIF-1 \u03b1 hydroxylases: Implications for oxygen sensing","volume":"116","author":"Metzen","year":"2003","journal-title":"J Cell Sci"},{"key":"B16-20250823","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1582-4934.2010.01030.x","article-title":"The role of HIF prolyl hydroxylases in tumour growth","volume":"14","author":"Jokilehto","year":"2010","journal-title":"J Cell Mol Med"},{"key":"B17-20250823","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"key":"B18-20250823","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.107.701516","article-title":"Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system","volume":"116","author":"Takeda","year":"2007","journal-title":"Circulation"},{"key":"B19-20250823","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccr.2009.09.029","article-title":"Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"B20-20250823","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar2575","article-title":"Hypoxia. Regulation of NFkappaB signalling during inflammation: The role of hydroxylases","volume":"11","author":"Oliver","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B21-20250823","first-page":"13","article-title":"Prolyl-hydroxylase 3: Evolving roles for an ancient signaling protein","volume":"2013","author":"Place","year":"2013","journal-title":"Hypoxia (Auckl)"},{"key":"B22-20250823","doi-asserted-by":"crossref","first-page":"BSR20170275","DOI":"10.1042\/BSR20170275","article-title":"Time-dependent inhibition of PHD2","volume":"37","author":"Tcholakov","year":"2017","journal-title":"Biosci Rep"},{"key":"B23-20250823","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: A 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B24-20250823","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1681\/ASN.2014121184","article-title":"Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling","volume":"27","author":"Souma","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B25-20250823","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI57301","article-title":"Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice","volume":"121","author":"Asada","year":"2011","journal-title":"J Clin Invest"},{"key":"B26-20250823","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/cells11040753","article-title":"The HIF\u03b1-stabilizing drug roxadustat increases the number of renal epo-producing Sca-1+ cells","volume":"11","author":"Jatho","year":"2022","journal-title":"Cells"},{"key":"B27-20250823","doi-asserted-by":"crossref","first-page":"e13768","DOI":"10.1111\/apha.13768","article-title":"Fate-mapping of erythropoietin-producing cells in mouse models of hypoxaemia and renal tissue remodelling reveals repeated recruitment and persistent functionality","volume":"234","author":"Dahl","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"B28-20250823","doi-asserted-by":"crossref","first-page":"e13826","DOI":"10.1111\/apha.13826","article-title":"EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis","volume":"235","author":"Kobayashi","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"B29-20250823","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B30-20250823","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/jpet.119.258731","article-title":"TP0463518, a novel prolyl hydroxylase inhibitor, specifically induces erythropoietin production in the liver","volume":"371","author":"Kato","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B31-20250823","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B32-20250823","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/2589977514666220401094724","article-title":"Belzutifan: A narrative drug review","volume":"14","author":"Visweswaran","year":"2022","journal-title":"Curr Drug Res Rev"},{"key":"B33-20250823","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"B34-20250823","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: A metaregression analysis","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B35-20250823","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ndt\/gfx315","article-title":"Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: A propensity score-matched analysis","volume":"33","author":"P\u00e9rez-Garc\u00eda","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B36-20250823","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2012-11-427765","article-title":"The gut in iron homeostasis: Role of HIF-2 under normal and pathological conditions","volume":"122","author":"Mastrogiannaki","year":"2013","journal-title":"Blood"},{"key":"B37-20250823","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcmd.2012.08.002","article-title":"Cell-specific regulation of ferroportin transcription following experimentally-induced acute anemia in mice","volume":"50","author":"Chiabrando","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"B38-20250823","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J Clin Invest"},{"key":"B39-20250823","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF-2\u03b1 axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"J Clin Invest"},{"key":"B40-20250823","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1002\/jcp.30247","article-title":"Erythroferrone structure, function, and physiology: Iron homeostasis and beyond","volume":"236","author":"Srole","year":"2021","journal-title":"J Cell Physiol"},{"key":"B41-20250823","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"B42-20250823","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"B43-20250823","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1515\/hsz-2011-0221","article-title":"Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: Identification of a hypoxia-responsive element in the TMPRSS6 promoter region","volume":"393","author":"Maurer","year":"2012","journal-title":"Biol Chem"},{"key":"B44-20250823","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nri.2017.103","article-title":"Regulation of immunity and inflammation by hypoxia in immunological niches","volume":"17","author":"Taylor","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B45-20250823","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/febs.15476","article-title":"If it\u2019s not one thing, HIF\u2019s another: Immunoregulation by hypoxia inducible factors in disease","volume":"287","author":"Hammond","year":"2020","journal-title":"FEBS J"},{"key":"B46-20250823","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"B47-20250823","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: Pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48-20250823","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"B49-20250823","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"B50-20250823","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: Pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv Ther"},{"key":"B51-20250823","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1744-9987.13717","article-title":"Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients","volume":"26","author":"Kanda","year":"2022","journal-title":"Ther Apher Dial"},{"key":"B52-20250823","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"B53-20250823","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: A phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B54-20250823","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"B55-20250823","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: A randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"B56-20250823","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial","volume":"121","author":"Hou","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"B57-20250823","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ekir.2021.12.025","article-title":"Randomized study on the efficacy of standard versus low roxadustat dose for anemia in patients on peritoneal dialysis","volume":"7","author":"Yang","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B58-20250823","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/1744-9987.13611","article-title":"Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan","volume":"25","author":"Nangaku","year":"2021","journal-title":"Ther Apher Dial"},{"key":"B59-20250823","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1744-9987.13686","article-title":"Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients","volume":"25","author":"Kanai","year":"2021","journal-title":"Ther Apher Dial"},{"key":"B60-20250823","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yexcr.2017.03.019","article-title":"Hypoxia and B cells","volume":"356","author":"Burrows","year":"2017","journal-title":"Exp Cell Res"},{"key":"B61-20250823","doi-asserted-by":"crossref","first-page":"11859","DOI":"10.21037\/apm-21-2916","article-title":"Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B62-20250823","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.transproceed.2021.10.022","article-title":"Experience with the use of a novel agent, hypoxia-inducible factor prolyl hydroxylase inhibitor, for posttransplant anemia in renal transplant recipients: A case report","volume":"54","author":"Naganuma","year":"2022","journal-title":"Transplant Proc"},{"key":"B63-20250823","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B64-20250823","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcph.1648","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: a placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients","volume":"60","author":"Provenzano","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B65-20250823","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B66-20250823","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B67-20250823","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B68-20250823","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B69-20250823","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B70-20250823","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS Study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B71-20250823","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","article-title":"Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: A single-center, prospective investigation","volume":"16","author":"Zhou","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B72-20250823","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B73-20250823","doi-asserted-by":"crossref","first-page":"105256","DOI":"10.1016\/j.phrs.2020.105256","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis","volume":"163","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"B74-20250823","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): Correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B75-20250823","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B76-20250823","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: A European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"B77-20250823","doi-asserted-by":"crossref","first-page":"103921","DOI":"10.1016\/j.ebiom.2022.103921","article-title":"Post-mortem liver and bone marrow iron quantification in haemodialysis patients: A prospective cohort study","volume":"77","author":"Carrilho","year":"2022","journal-title":"EBioMedicine"},{"key":"B78-20250823","doi-asserted-by":"crossref","first-page":"442","DOI":"10.52586\/4958","article-title":"Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease","volume":"26","author":"Bhandari","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B79-20250823","doi-asserted-by":"crossref","first-page":"e133690","DOI":"10.1172\/jci.insight.133690","article-title":"Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS","volume":"6","author":"Yu","year":"2021","journal-title":"JCI Insight"},{"key":"B80-20250823","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"B81-20250823","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1\u03b1 activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J Biol Chem"},{"key":"B82-20250823","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1093\/eurheartj\/ehw156","article-title":"Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia","volume":"37","author":"Marsch","year":"2016","journal-title":"Eur Heart J"},{"key":"B83-20250823","doi-asserted-by":"crossref","first-page":"18284","DOI":"10.1074\/jbc.RA120.015238","article-title":"Serum lipoprotein-derived fatty acids regulate hypoxia-inducible factor","volume":"295","author":"Shao","year":"2020","journal-title":"J Biol Chem"},{"key":"B84-20250823","doi-asserted-by":"crossref","first-page":"e016318","DOI":"10.1161\/JAHA.119.016318","article-title":"Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events","volume":"9","author":"Willeit","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B85-20250823","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B86-20250823","doi-asserted-by":"crossref","first-page":"798053","DOI":"10.3389\/fphar.2022.798053","article-title":"Daprodustat accelerates high phosphate-induced calcification through the activation of hif-1 signaling","volume":"13","author":"T\u00f3th","year":"2022","journal-title":"Front Pharmacol"},{"key":"B87-20250823","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2022.01.002","article-title":"Hypoxia inducible factor 1\u03b1 inhibitor PX-478 reduces atherosclerosis in mice","volume":"344","author":"Villa-Roel","year":"2022","journal-title":"Atherosclerosis"},{"key":"B88-20250823","doi-asserted-by":"crossref","first-page":"664258","DOI":"10.3389\/fcell.2021.664258","article-title":"Whole-body prolyl hydroxylase domain (phd) 3 deficiency increased plasma lipids and hematocrit without impacting plaque size in low-density lipoprotein receptor knockout mice","volume":"9","author":"Demandt","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B89-20250823","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0003319716662423","article-title":"Hypoxia in atherogenesis","volume":"68","author":"Ferns","year":"2017","journal-title":"Angiology"},{"key":"B90-20250823","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/ATVBAHA.121.316495","article-title":"Roxadustat does not affect platelet production, activation, and thrombosis formation","volume":"41","author":"Zhao","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B91-20250823","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2008.05.029","article-title":"Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis","volume":"52","author":"Streja","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B92-20250823","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000522071","article-title":"Threshold of serum ferritin to discriminate against those at greater risk of platelet increase during treatment with hypoxia-inducible factor prolyl hydroxylase domain inhibitor","volume":"145","author":"Ogawa","year":"2022","journal-title":"Acta Haematol"},{"key":"B93-20250823","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B94-20250823","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B96-20250823","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0175-3","article-title":"Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: Does geography matter?","volume":"74","author":"De Nicola","year":"2014","journal-title":"Drugs"},{"key":"B97-20250823","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2018-06-854976","article-title":"Hypoxia and thrombosis","volume":"132","author":"Prchal","year":"2018","journal-title":"Blood"},{"key":"B98-20250823","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb Res"},{"key":"B99-20250823","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","article-title":"Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"4","author":"Gangaraju","year":"2020","journal-title":"Blood Adv"},{"key":"B100-20250823","doi-asserted-by":"crossref","first-page":"813550","DOI":"10.3389\/fcvm.2022.813550","article-title":"The influence of environmental hypoxia on hemostasis\u2014A systematic review","volume":"9","author":"Treml","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B101-20250823","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/ham.2021.0075","article-title":"Platelets and high-altitude exposure: A meta-analysis","volume":"23","author":"Wang","year":"2022","journal-title":"High Alt Med Biol"},{"key":"B102-20250823","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/0284186X.2017.1301680","article-title":"HIF-1 in cancer therapy: Two decade long story of a transcription factor","volume":"56","author":"Soni","year":"2017","journal-title":"Acta Oncol"},{"key":"B103-20250823","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/0008-5472.CAN-18-2674","article-title":"Genome-wide interrogation of human cancers identifies egln1 dependency in clear cell ovarian cancers","volume":"79","author":"Price","year":"2019","journal-title":"Cancer Res"},{"key":"B104-20250823","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"key":"B105-20250823","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0192623319880445","article-title":"Carcinogenicity assessment of daprodustat (gsk1278863), a hypoxia-inducible factor (hif)-prolyl hydroxylase inhibitor","volume":"48","author":"Adams","year":"2020","journal-title":"Toxicol Pathol"},{"key":"B106-20250823","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B107-20250823","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"B108-20250823","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B109-20250823","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/CIRCULATIONAHA.116.021494","article-title":"Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2\u03b1","volume":"133","author":"Dai","year":"2016","journal-title":"Circulation"},{"key":"B110-20250823","doi-asserted-by":"crossref","first-page":"109524","DOI":"10.1016\/j.cellsig.2020.109524","article-title":"Role of oxygen and the HIF-pathway in polycystic kidney disease","volume":"69","author":"Buchholz","year":"2020","journal-title":"Cell Signal"},{"key":"B111-20250823","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B112-20250823","article-title":"Stabilization of hypoxia-inducible factor 1\u03b1 by cobalt chloride impairs podocyte morphology and slit-diaphragm function","author":"Nakuluri","journal-title":"J Cell Biochem"},{"key":"B113-20250823","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/ndt\/gfaa074","article-title":"Chronic hypoxia exacerbates diabetic glomerulosclerosis through mesangiolysis and podocyte injury in db\/db mice","volume":"35","author":"Takahashi","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B114-20250823","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama","year":"2021","journal-title":"Clin Kidney J"},{"key":"B115-20250823","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii","year":"2021","journal-title":"BMC Nephrol"},{"key":"B116-20250823","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao","year":"2019","journal-title":"iScience"},{"key":"B117-20250823","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2215\/CJN.06920712","article-title":"Hypothyroidism and mortality among dialysis patients","volume":"8","author":"Rhee","year":"2013","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2022040413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:49:19Z","timestamp":1786132159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2022040413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":116,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2022040413","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}